IMPACT Therapeutics Inc is a China-based company primarily engaged in the research, development, and commercialization of pharmaceutical products. The Company is principally engaged in the research and development of synthetic lethality-based precision anti-cancer therapies. The Company's product pipeline is primarily composed of Senaparib, as well as novel antibody-drug conjugates (ADCs) and degrader candidates. The Company distributes its products within the domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-05	HK$12.63	-2.09%	387,000
26-08-05	HK$12.90	+6.35%	557,159
26-08-04	HK$12.13	+4.57%	576,212
26-08-03	HK$11.60	-12.32%	569,480
26-07-31	HK$13.23	+14.84%	807,400

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

11.10CNY

Average target price

28.52CNY

Spread / Average Target

+156.83%

Consensus

Net sales - Rate of surprise

Company calendar

Delayed Hong Kong S.E. Other stock markets 11:53:17 2026-08-05 pm EDT			5-day change	1st Jan Change
12.63 ^HKD	-2.09%		+9.64%	-

Jul. 31	IMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand	CI
Jul. 27	IMPACT Therapeutics, Inc Announces IMP3201 As A Preclinical Candidate, A First-In-Class CEACAM5-Targeted Dual-Payload ADC	CI

Market Cap	3.07B 3.56B 454M 393M 367M 337M 637M 43.19B 644M 4.31B 1.69B 21.61B 1.71B 1.67B 71.57B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	2.22B 2.58B 329M 285M 266M 245M 462M 31.32B 467M 3.13B 1.23B 15.67B 1.24B 1.21B 51.91B	EV / Sales 2026 *	7.73x	EV / Sales 2027 *	1.89x
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

Jul. 31	IMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand	CI
Jul. 27	IMPACT Therapeutics, Inc Announces IMP3201 As A Preclinical Candidate, A First-In-Class CEACAM5-Targeted Dual-Payload ADC	CI
Jul. 27	Impact Therapeutics Nominates Preclinical Candidate for GI Cancers	MT
Jul. 20	Impact Therapeutics Announces Clinical Data for Senaparib, IMP4297, and IMP1707 Accepted for Poster Presentation at 2026 ESMO Congress	CI
Jun. 07	Impact Therapeutics Nets HK$120 Million From Full Exercise of IPO Overallotment Option	MT
Jun. 01	Impact Therapeutics, Inc Presents Phase 1/2 Clinical Data for Imp1734 At 2026 Asco Annual Meeting	CI
May. 13	Hong Kong Stocks Eke Out Gains; Metis TechBio, Impact Therapeutics Shine on Debut	MT
May. 12	Impact Therapeutics Jumps 77% in Hong Kong Trading Debut	MT
May. 12	Impact Therapeutics Nets HK$759.5 Million From Hong Kong IPO Ahead of Debut	MT
May. 12	IMPACT Therapeutics, Inc has completed an IPO in the amount of HKD 843.7377 million.	CI
May. 12	Impact Therapeutics says final offer price under global offering of HK$20.10 per H share	RE
May. 05	IMPACT Therapeutics, Inc has filed an IPO in the amount of HKD 913.20964 million.	CI
May. 04	IMPACT Therapeutics, Inc Reports Earnings Results for the Full Year Ended December 31, 2025	CI

1 day	-2.95%
1 week	+8.68%
Current month	-5.37%
1 month	-38.93%

IMPACT Therapeutics, Inc Stock

Stocks

7630

CNE100007LG4

Biotechnology & Medical Research

Valuation: IMPACT Therapeutics, Inc

Chart: IMPACT Therapeutics, Inc

Latest news : IMPACT Therapeutics, Inc

Press Releases: IMPACT Therapeutics, Inc

Quotes and Performance

Course Extremes

Managers and Directors: IMPACT Therapeutics, Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Net sales - Rate of surprise

1 week	11.42	13.5
1 month	10.31	21
Current year	10.31	47.98
1 year	10.31	47.98
3 years	10.31	47.98
5 years	10.31	47.98
10 years	10.31	47.98

Manager	Title	Age	Since
Sui Xiong Cai CEO	Chief Executive Officer	69	2014-05-31
Hui Jun Deng DFI	Director of Finance/CFO	51	2024-04-30
Yan Hua Xu CTO	Chief Tech/Sci/R&D Officer	44	2024-12-31

Director	Title	Age	Since
Ye Tian BRD	Director/Board Member	69	2014-05-31
Sui Xiong Cai BRD	Director/Board Member	69	2014-05-31
Ning Ma BRD	Director/Board Member	44	2025-02-28

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMPACT THERAPEUTICS, INC	-2.95%	+8.68%	-	-	427M
LONZA GROUP AG	+0.90%	-2.33%	+0.68%	+13.87%	48B
REVOLUTION MEDICINES, INC.	+1.98%	+9.05%	+413.94%	+532.17%	41.13B
IQVIA HOLDINGS INC.	+3.44%	-4.65%	+28.34%	+8.81%	37.56B
BEONE MEDICINES AG	+1.40%	+0.10%	+6.61%	+61.93%	35.91B
CELLTRION, INC.	+2.42%	+5.72%	+12.38%	+44.79%	29.86B
ASCENDIS PHARMA A/S	-0.16%	-3.11%	-	-	16.12B
MEDPACE HOLDINGS, INC.	+2.20%	+0.48%	+34.71%	+127.15%	16.05B
EUROFINS SCIENTIFIC SE	+1.25%	+1.52%	+4.62%	+18.26%	13.76B
ICON PUBLIC LIMITED COMPANY	+4.25%	-8.23%	-1.49%	-35.46%	12.1B
Average	+1.47%	+0.40%	+62.47%	+96.44%	25.09B
Weighted average by Cap.	+1.90%	+0.01%	+82.48%	+120.78%

	2026 *	2027 *
Net sales	288M 334M 42.59M 36.89M 34.39M 31.63M 59.71M 4.05B 60.37M 404M 159M 2.03B 160M 156M 6.71B	941M 1.09B 139M 121M 113M 104M 195M 13.26B 198M 1.32B 519M 6.63B 524M 512M 21.97B
Net income	-	-
Net Debt	-842M -979M -125M -108M -101M -92.65M -175M -11.86B -177M -1.18B -465M -5.94B -469M -458M -19.66B	-1.29B -1.5B -191M -165M -154M -142M -267M -18.13B -270M -1.81B -710M -9.07B -716M -700M -30.05B